Table 2.
Logistic regression analyses of the association between TMAO levels and clinical outcomes
| OR (95% CI) for 3-month unfavorable functional outcome | P value | OR (95% CI) for 3-month mortality | P value | |
|---|---|---|---|---|
| Unadjusted model | ||||
| TMAO level | ||||
| First quartile | Reference | Reference | ||
| Second quartile | 1.56 (0.73–3.33) | 0.250 | 1.60 (0.53–4.83) | 0.408 |
| Third quartile | 2.78 (1.29–5.98) | 0.009 | 2.52 (0.88–7.20) | 0.084 |
| Fourth quartile | 3.09 (1.43– 6.65) | 0.004 | 5.64 (2.08–15.30) | 0.001 |
| Adjusted model | ||||
| TMAO level | ||||
| First quartile | Reference | Reference | ||
| Second quartile | 2.01 (0.79–5.11) | 0.143 | 1.43 (0.34–6.05) | 0.627 |
| Third quartile | 2.65 (0.96–7.34) | 0.061 | 1.89 (0.48–7.39) | 0.320 |
| Fourth quartile | 3.63 (1.34–9.82) | 0.011 | 4.27 (1.07– 17.07) | 0.040 |
The multivariate model was adjusted for demographic characteristics, hypertension, coronary heart disease, body mass index, NIHSS score, DWI-ASPECT score 0–7, stroke subtypes, and homocysteine and low-density lipoprotein levels